Research showing that Mcl-1 upregulation significantly contributes to resistance against widely used anticancer therapies including antitubulins (Wertz et al., 2011), HER2-targeting agents (Bashari et al., 2016), points to Mcl-1 as an important target in breast cancer therapy. The gene discussed is ERBB2; the disease is breast carcinoma.